Risk-assessment of R packages in a Biopharmaceutical Regulatory Setting.
Abstract Number:
2338
Submission Type:
Contributed Abstract
Contributed Abstract Type:
Paper
Participants:
Juliane Manitz (1), Antal Martinecz (2), Doug Kelkhoff (3)
Institutions:
(1) EMD Serono, N/A, (2) Certara, N/A, (3) Roche, N/A
Co-Author(s):
First Author:
Presenting Author:
Abstract Text:
This contribution reflects on framework and tools by the R Validation Hub for risk-based assessment of R packages within validated infrastructure.
The R Validation Hub is a cross-industry initiative, led by approximately 10 organizations with frequent involvement from health authorities. The R validation Hub is funded by the R Consortium and has the mission to support the adoption of R within regulated industries, with an emphasis on biopharmaceuticals.
We will discuss the framework for the risk-based assessment of R packages, that has been utilized by key pharma companies across the industry. We will also showcase the {riskmetric} R package, that evaluates the risk of an R package using a specified set of metrics and validation criteria, and the {riskassessment} app, that augments the utility of the {riskmetric} package with a Shiny app front end. Lastly, we will outline a prototype of a technical framework for a 'repository' of R packages with accompanying evidence of their quality and the assessment criteria.
Keywords:
R Package|Risk assessment |Open-source software|Regulated environment|validation|
Sponsors:
Biopharmaceutical Section
Tracks:
Miscellaneous
Can this be considered for alternate subtype?
Yes
Are you interested in volunteering to serve as a session chair?
Yes
I have read and understand that JSM participants must abide by the Participant Guidelines.
Yes
I understand that JSM participants must register and pay the appropriate registration fee by June 1, 2024. The registration fee is non-refundable.
I understand
You have unsaved changes.